European regulators publish ambitious workplan to support the 10 priority areas of ACT EU

On August 30th, the European Commission, Heads of Medicines Agencies and European Medicines Agencies released a workplan to address the ten priority areas of the Accelerating Clinical Trials in the E.U. initiative, intended to make the region a better home for multi-national clinical trials. The workplan unveils a wealth of deliverables over the next two years that aim to support efficient multi-national processes with streamlined support from regulators.

ACT EU aims to address the paucity of multi-national clinical trials in the European innovative environment

The E.U. has an extensive life science research and healthcare sector to support innovation. The E.U. has a rich pharmaceutical industry that spent EUR 39 billion on research and development alone in 2020, according to an EFPIA report on its members’ expenditures.

Fill out the form to read the full article.